Akoya Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKYA Nasdaq 2836 www.akoyabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akoya Biosciences, Inc.

Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal - Jan 10th, 2025 12:49 pm
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers - Jan 10th, 2025 12:00 pm
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions - Dec 10th, 2024 1:15 pm
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone - Dec 9th, 2024 1:00 pm
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Nov 17th, 2024 1:11 pm
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Nov 16th, 2024 1:04 pm
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Nov 15th, 2024 7:18 am
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Nov 14th, 2024 10:10 pm
Akoya: Q3 Earnings Snapshot - Nov 14th, 2024 9:09 pm
Akoya Biosciences Reports Third Quarter 2024 Financial Results - Nov 14th, 2024 9:00 pm
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Nov 5th, 2024 1:00 pm
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - Oct 28th, 2024 12:30 pm
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - Oct 7th, 2024 12:00 pm
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - Oct 3rd, 2024 8:00 pm
Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint - Aug 7th, 2024 12:43 pm
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates - Aug 5th, 2024 9:10 pm
Akoya: Q2 Earnings Snapshot - Aug 5th, 2024 8:07 pm
Akoya Biosciences Reports Second Quarter 2024 Financial Results - Aug 5th, 2024 8:00 pm
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences - Jul 15th, 2024 8:00 pm
While institutions own 21% of Akoya Biosciences, Inc. (NASDAQ:AKYA), private equity firms are its largest shareholders with 49% ownership - Jul 11th, 2024 7:20 pm